The Oxford-based biotech company has secured £13.2m to progress world’s vital treatment development

Decision will create opportunity for therapy to be used earlier in the treatment pathway

Notable first clearance for R21/Matrix-M malaria vaccine for use in a specific country

The trial will monitor patients across Europe for 24 months as they are treated with tildrakizumab

Partnership will develop technology to screen and diagnose Lyme disease and diabetes

Company’s candidate, in combination with MSD’s Keytruda, receives PRIME designation

Treatment concerns adults and adolescents with stage IIB or IIC melanoma skin cancer

Updated Date: Mon, 03 Apr 2023 00:00:00 EDT

Updated Date: Mon, 03 Apr 2023 00:00:00 EDT

Updated Date: Mon, 03 Apr 2023 00:00:00 EDT